Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10mg Obicetrapib in Participants With HeFH and/or ASCVD Who Are Not Adequately Controlled by Their Lipid Modifying Therapies

NCT05142722 is registered in ClinicalTrials.gov with NewAmsterdam Pharma as lead sponsor.

NCT NCT05142722
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05142722 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10mg Obicetrapib in Participants With HeFH and/or ASCVD Who Are Not Adequately Controlled by Their Lipid Modifying Therapies
Lead sponsor
NewAmsterdam Pharma
Phase
Phase 3
Overall status
Completed
Start date
December 15, 2021
Completion date
September 26, 2024
Enrollment
2,530 (actual)
Sites
181

Conditions

As the registry lists them; a condition with its own page is linked.

atherosclerotic cardiovascular disease, dyslipidemias, familial hypercholesterolemia, high cholesterol, hypercholesterolemia